Anemia Clinical Trials

Find Anemia Clinical Trials Near You

Fibrinogen in Liver Transplant Subjects (FITS)

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The study is a prospective, multi-centered, unblinded, randomized controlled pilot study. The primary objective is to compare functional hemostatic capacity of two approved products Intercept Fibrinogen Complex (IFC) to Standard Cryoprecipitate Antihemophilic Factor (AHF) for liver transplant patients with bleeding and hypofibrinogenemia to determine impact of earlier access to a concentrated source of fibrinogen in a goal-directed manner.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 18 years of age or older

• Scheduled to undergo cadaveric liver transplant

• Meets at least one of the following criteria: Baseline fibrinogen \<200 mg/dL or clinically significant visoelastic testing

• Meets any one of the following criteria: Alcoholic cirrhosis, Metabolic dysfunction associated steatohepatitis (MASH) (previously known as Nonalcoholic Steatohepatitis (NASH)), HCV infection

Locations
United States
Ohio
University of Cincinnati
RECRUITING
Cincinnati
Contact Information
Primary
Meghan Huff Research Nurse, BSN
mhuff@pitt.edu
6185789309
Time Frame
Start Date: 2026-05-21
Estimated Completion Date: 2028-03-01
Participants
Target number of participants: 60
Treatments
Active_comparator: Standard Antihemophilic Factor (AHF)
AHF is the standard of care fibrinogen product often used in liver transplant cases. The procedures to use AHF include requesting the order of this product and then waiting for the product to be thawed for use, which can take approximately 10-15 minutes. Subjects assigned to this group will receive all standard of care procedures, including the use of AHF if required during their scheduled surgery.
Active_comparator: Intercept Fibrinogen Complex (IFC)
IFC is an approved fibrinogen product that is not typically stored in the OR for liver transplant cases. Subjects assigned to this group will receive standard of care procedures, with the addition of IFC being readily available in their designated OR to eliminate any delay if they are to require the use of a fibrinogen product.
Sponsors
Leads: Trauma Hemostatis and Oxygenation Research (THOR) Network

This content was sourced from clinicaltrials.gov

Similar Clinical Trials